248 related articles for article (PubMed ID: 35854180)
1. Metastatic Adenoid Cystic Carcinoma: Genomic Landscape and Emerging Treatments.
de Sousa LG; Jovanovic K; Ferrarotto R
Curr Treat Options Oncol; 2022 Aug; 23(8):1135-1150. PubMed ID: 35854180
[TBL] [Abstract][Full Text] [Related]
2. Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas Defines Molecular Subtypes and Identifies Therapeutic Targets.
Ferrarotto R; Mitani Y; McGrail DJ; Li K; Karpinets TV; Bell D; Frank SJ; Song X; Kupferman ME; Liu B; Lee JJ; Glisson BS; Zhang J; Aster JC; Lin SY; Futreal PA; Heymach JV; El-Naggar AK
Clin Cancer Res; 2021 Feb; 27(3):852-864. PubMed ID: 33172898
[TBL] [Abstract][Full Text] [Related]
3. Molecular Profiling and the Impact of Treatment on Outcomes in Adenoid Cystic Carcinoma Type I and II.
Hanna GJ; Grover P; Elliott A; McGrath J; Xiu J; Sukari A; Johnson JM; Wise-Draper T
Clin Cancer Res; 2024 May; 30(10):2225-2232. PubMed ID: 38416410
[TBL] [Abstract][Full Text] [Related]
4. Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors.
Ferrarotto R; Mitani Y; Diao L; Guijarro I; Wang J; Zweidler-McKay P; Bell D; William WN; Glisson BS; Wick MJ; Kapoun AM; Patnaik A; Eckhardt G; Munster P; Faoro L; Dupont J; Lee JJ; Futreal A; El-Naggar AK; Heymach JV
J Clin Oncol; 2017 Jan; 35(3):352-360. PubMed ID: 27870570
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Recurrent or Metastatic Adenoid Cystic Carcinoma.
de Sousa LG; Neto FL; Lin J; Ferrarotto R
Curr Oncol Rep; 2022 May; 24(5):621-631. PubMed ID: 35212920
[TBL] [Abstract][Full Text] [Related]
6. Adenoid Cystic Carcinoma from the salivary and lacrimal glands and the breast: Different clinical outcomes to the same tumor.
Emerick C; Mariano FV; Vargas PA; Nör JE; Squarize CH; Castilho RM
Crit Rev Oncol Hematol; 2022 Nov; 179():103792. PubMed ID: 35973662
[TBL] [Abstract][Full Text] [Related]
7. Systemic and Targeted Therapies in Adenoid Cystic Carcinoma.
Kacew AJ; Hanna GJ
Curr Treat Options Oncol; 2023 Jan; 24(1):45-60. PubMed ID: 36637743
[TBL] [Abstract][Full Text] [Related]
8. Diffuse Staining for Activated NOTCH1 Correlates With NOTCH1 Mutation Status and Is Associated With Worse Outcome in Adenoid Cystic Carcinoma.
Sajed DP; Faquin WC; Carey C; Severson EA; H Afrogheh A; A Johnson C; Blacklow SC; Chau NG; Lin DT; Krane JF; Jo VY; Garcia JJ; Sholl LM; Aster JC
Am J Surg Pathol; 2017 Nov; 41(11):1473-1482. PubMed ID: 28914715
[TBL] [Abstract][Full Text] [Related]
9. A Review of the Molecular Landscape of Adenoid Cystic Carcinoma of the Lacrimal Gland.
Powell SK; Kulakova K; Kennedy S
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762061
[TBL] [Abstract][Full Text] [Related]
10. Spatio-Temporal Genomic Heterogeneity, Phylogeny, and Metastatic Evolution in Salivary Adenoid Cystic Carcinoma.
Liu B; Mitani Y; Rao X; Zafereo M; Zhang J; Zhang J; Futreal PA; Lozano G; El-Naggar AK
J Natl Cancer Inst; 2017 Oct; 109(10):. PubMed ID: 29117356
[TBL] [Abstract][Full Text] [Related]
11. Adenoid cystic carcinoma: A review of recent advances, molecular targets, and clinical trials.
Dillon PM; Chakraborty S; Moskaluk CA; Joshi PJ; Thomas CY
Head Neck; 2016 Apr; 38(4):620-7. PubMed ID: 25487882
[TBL] [Abstract][Full Text] [Related]
12. MYB-fusions and other potential actionable targets in adenoid cystic carcinoma.
Ferrarotto R; Heymach JV; Glisson BS
Curr Opin Oncol; 2016 May; 28(3):195-200. PubMed ID: 26974847
[TBL] [Abstract][Full Text] [Related]
13. Genomics in non-adenoid cystic group of salivary gland cancers: one or more druggable entities?
Cavalieri S; Platini F; Bergamini C; Resteghini C; Galbiati D; Bossi P; Perrone F; Tamborini E; Quattrone P; Licitra L; Locati LD; Alfieri S
Expert Opin Investig Drugs; 2019 May; 28(5):435-443. PubMed ID: 30897975
[TBL] [Abstract][Full Text] [Related]
14. Adenoid cystic carcinoma: emerging role of translocations and gene fusions.
Wysocki PT; Izumchenko E; Meir J; Ha PK; Sidransky D; Brait M
Oncotarget; 2016 Oct; 7(40):66239-66254. PubMed ID: 27533466
[TBL] [Abstract][Full Text] [Related]
15. Genetic hallmarks of recurrent/metastatic adenoid cystic carcinoma.
Ho AS; Ochoa A; Jayakumaran G; Zehir A; Valero Mayor C; Tepe J; Makarov V; Dalin MG; He J; Bailey M; Montesion M; Ross JS; Miller VA; Chan L; Ganly I; Dogan S; Katabi N; Tsipouras P; Ha P; Agrawal N; Solit DB; Futreal PA; El Naggar AK; Reis-Filho JS; Weigelt B; Ho AL; Schultz N; Chan TA; Morris LG
J Clin Invest; 2019 Oct; 129(10):4276-4289. PubMed ID: 31483290
[TBL] [Abstract][Full Text] [Related]
16. AL101, a gamma-secretase inhibitor, has potent antitumor activity against adenoid cystic carcinoma with activated NOTCH signaling.
Ferrarotto R; Mishra V; Herz E; Yaacov A; Solomon O; Rauch R; Mondshine A; Motin M; Leibovich-Rivkin T; Davis M; Kaye J; Weber CR; Shen L; Pearson AT; Rosenberg AJ; Chen X; Singh A; Aster JC; Agrawal N; Izumchenko E
Cell Death Dis; 2022 Aug; 13(8):678. PubMed ID: 35931701
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands.
Agulnik M; Cohen EW; Cohen RB; Chen EX; Vokes EE; Hotte SJ; Winquist E; Laurie S; Hayes DN; Dancey JE; Brown S; Pond GR; Lorimer I; Daneshmand M; Ho J; Tsao MS; Siu LL
J Clin Oncol; 2007 Sep; 25(25):3978-84. PubMed ID: 17761983
[TBL] [Abstract][Full Text] [Related]
18. Current opinions on diagnosis and treatment of adenoid cystic carcinoma.
Fang Y; Peng Z; Wang Y; Gao K; Liu Y; Fan R; Zhang H; Xie Z; Jiang W
Oral Oncol; 2022 Jul; 130():105945. PubMed ID: 35662026
[TBL] [Abstract][Full Text] [Related]
19. Concomitant inhibition of epidermal growth factor and vascular endothelial growth factor receptor tyrosine kinases reduces growth and metastasis of human salivary adenoid cystic carcinoma in an orthotopic nude mouse model.
Younes MN; Park YW; Yazici YD; Gu M; Santillan AA; Nong X; Kim S; Jasser SA; El-Naggar AK; Myers JN
Mol Cancer Ther; 2006 Nov; 5(11):2696-705. PubMed ID: 17121916
[TBL] [Abstract][Full Text] [Related]
20. Prognosis and management of recurrent and/or metastatic head and neck adenoid cystic carcinoma.
Lorini L; Ardighieri L; Bozzola A; Romani C; Bignotti E; Buglione M; Guerini A; Lombardi D; Deganello A; Tomasoni M; Bonini SA; Sigala S; Farina D; Ravanelli M; Bossi P
Oral Oncol; 2021 Apr; 115():105213. PubMed ID: 33578204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
